Download PDFPDF

784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address